2014 ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the Bio
‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network
Abstract: Ustekinumab showed a better overall drug survival than etanercept, and a trend towards a better overall drug survival than adalimumab. After 1 year, patients reported to be 'happy' in 79% of episodes and 'unhappy' in 21%. We introduced the new concept of 'happy' drug survival because the proportion of on-drug patients with good quality of life is an important indicator for treatment success.
Search citation statements
Paper Sections
Select...
71
19
8
5
Citation Types
20
61
2
13
Year Published
2014
2024
Publication Types
Select...
94
2
Relationship
5
91
Authors
Journals
Cited by 96 publications
(96 citation statements)
References 37 publications
20
61
2
13
“…With the current report, we confirmed previously published studies where ustekinumab showed the highest drug survival compared to adalimumab, etanercept, and infliximab . Moreover, we supported the findings by Egeberg et al .…”
Section: Discussionsupporting
confidence: 93%
“…With the current report, we confirmed previously published studies where ustekinumab showed the highest drug survival compared to adalimumab, etanercept, and infliximab . Moreover, we supported the findings by Egeberg et al .…”
Section: Discussionsupporting
confidence: 93%
“…Our data confirmed previously reported data from several registrybased studies (Brunasso, Puntoni, & Massone, 2012;Iskandar, et al 2015May18;Menting, Sitaram, & Bonnerjee-van der Stok, 2014;van den Reek et al, 2014;Warren et al, 2015). In a retrospective cohort study evaluating tolerability and safety of biological drugs (adalimumab, efalizumab, etanercept, and infliximab) in 108 PsO patients infliximab was significantly associated with a shorter adherence to therapy compared with adalimumab, etanercept, and efalizumab (Brunasso et al, 2012).…”
Section: Discussionsupporting
confidence: 93%
“…Consistent with some, but not all, previous studies, we found that drug survival rates for the first and second courses of biologic therapies were comparable ( Menting et al., 2014 , van den Reek et al., 2014b ). However, compared with those studies, our research has important strengths: our sample size was much larger, thereby giving the study more power for the investigation of comparative second-line biologic survival, and we included patients from multiple dermatology centers, thus ensuring high external validity.…”
Section: Discussionsupporting
confidence: 92%
